Umbilical Cord Mesenchymal Stem Cell Secretome in Severe Erectile Dysfunction Non-responsive to Sildenafil

Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexMale
Age40-65
SponsorIndonesia University

About this trial

The study is an experimental pre-post-test design involving 10 patients with severe ED non-responsive to sildenafil. Safety parameters included pain, hematoma, local bleeding, and infection, while efficacy was measured using the IIEF-5 questionnaire, EHS, and morning erection.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Men aged 40-65 years who undergo treatment at the Andrology Clinic of RSUD Dr. Soetomo.

Severe erectile dysfunction caused by organic factors for at least 6 months, based on an IIEF-5 score of 5-7

History of undergoing treatment with sildenafil 100 mg for four sessions.

Evaluation of IIEF-5 score < 22 and not meeting the MCID criteria, defined as an IIEF-5 score increase of less than 4

Disqualifiers

Anatomical abnormalities of the penis that are clinically visible, such as Peyronie's disease, a history of priapism, a history of penile implants, skin irritation, and lesions in the area surrounding the penile skin.

Active and significant systemic or local infection.

History of bleeding or blood clotting disorder therapy.

History of systemic autoimmune disorders and immunosuppressive treatment

Trial design

Design model

Single group

Treatments tested in this trial

  • uc-msc secretome intra cavernous injection

    Combination product

    UC-MSC secretome was obtained from UC-MSC cultures with 80% confluence in serum-free medium after 24 hours of incubation The VEGF level in the secretome given was 1400 pg/ml. The intervention was the administration of 0.5 mL/site of secretome injection injected intra-cavernous to all subjects using a 22-gauge needle according to a sterile protocol. The same volume was given at bilateral sites of the penile shaft. The intra-cavernous injection sites were in the right and left dorsolateral regions of the penis. After the intervention, tolerability was assessed by observing and questioning the subjects regarding pain during injection.

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: pretreatment group: severe eretile dysfunction non responsive Sildenafil with no injectionExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Visual analog scale

A visual analog scale is used for measuring pain. The patient will be asked to describe the pain on a scale of 1-10. Scale 1 means no pain and 10 means very great pain. A higher score indicates a worse outcome.

Time frame
one hour and one year
2

Hematomes

Hematomes means blue discoloration. 0 scale means there is no discoloration and 1 means there is a discoloration.

Time frame
one hour
3

Bleeding

Bleeding is one of the outcomes of the research. If there is a bleeding, it would be marked as 1; if there is no bleeding, it would be marked as 0.

Time frame
one hour
4

Erection hardness score

Rapid diagnostic tool to evaluate erectile dysfunction. There are 4 score; 1 indicates severe erectile dysfunction (Worst) and 4 indicates there is optimal erection. (Good)

Time frame
one year

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: